Wolf M. Mineral (Mal)Adaptation to kidney disease-young investigator award address: American society of nephrology kidney week 2014. Clin J Am Soc Nephrol. 2015;10(10):1875–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henderson RG, Ledingham JG, Norman AW, Oliver DO, Preston C, Russell RG, et al. 1,25-dihydroxycholecalciferol in patients with chronic renal failure. Proc Eur Dial Transplant Assoc. 1973;10:202–9.

CAS  PubMed  Google Scholar 

Henderson RG, Russell RG, Ledingham JG, Smith R, Oliver DO, Walton RJ, et al. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet. 1974;1(7854):379–84.

Article  CAS  PubMed  Google Scholar 

Nielsen HE, Christensen MS, Melsen F, Romer FK, Hansen HE. Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure. Clin Endocrinol (Oxf). 1977;7(Suppl):67s–72s.

PubMed  Google Scholar 

Pietrek J, Kokot F, Kuska J. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency. Int Urol Nephrol. 1978;10(2):153–60.

Article  CAS  PubMed  Google Scholar 

Scialla JJ. Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. Curr Opin Nephrol Hypertens. 2015;24(3):260–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10(5):268–78.

Article  CAS  PubMed  Google Scholar 

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–83.

Article  CAS  PubMed  Google Scholar 

Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal Disease. Hypertension. 2001;38(4):938–42.

Article  CAS  PubMed  Google Scholar 

London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007;18(2):613–20.

Article  CAS  PubMed  Google Scholar 

London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.

Article  CAS  PubMed  Google Scholar 

Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119–27.

Article  CAS  PubMed  Google Scholar 

Danese MD, Halperin M, Lowe KA, Bradbury BD, Do TP, Block GA. Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. Nephrol Dial Transplant. 2015;30(8):1336–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol. 2013;8(12):2132–40.

Article  PubMed  PubMed Central  Google Scholar 

Block GA, Yusuf AA, Danese MD, Wirtz HS, Hu Y, Do TP, et al. Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis. BMC Nephrol. 2016;17(1):166.

Article  PubMed  PubMed Central  Google Scholar 

Neri L, Kreuzberg U, Bellocchio F, Brancaccio D, Barbieri C, Canaud B, et al. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study. Nephrol Dial Transplant. 2019;34(4):682–91.

Article  CAS  PubMed  Google Scholar 

Filipozzi P, Ayav C, Ngueyon Sime W, Laurain E, Kessler M, Brunaud L, et al. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study. BMJ Open. 2017;7(3):e011482.

Article  PubMed  PubMed Central  Google Scholar 

Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM. Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis. Am J Kidney Dis. 2020;76(3):321–30.

Article  CAS  PubMed  Google Scholar 

Palmer SC, Teixeira-Pinto A, Saglimbene V, Craig JC, Macaskill P, Tonelli M, et al. Association of drug effects on serum parathyroid hormone, phosphorus, and calcium levels with mortality in CKD: a meta-analysis. Am J Kidney Dis. 2015;66(6):962–71.

Article  CAS  PubMed  Google Scholar 

Yeung W-CG, Palmer SC, Strippoli GFM, Talbot B, Shah N, Hawley CM, et al. Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2023;82(5):543–58.

Karaboyas A, Muenz D, Fuller DS, Desai P, Lin T-C, Robinson BM, et al. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J Kidney Dis. 2022;79(3):362–73.

Article  CAS  PubMed  Google Scholar 

Hall R, Platt A, Wilson J, Ephraim PL, Hwang AS, Chen A, et al. Trends in mineral metabolism treatment strategies in patients receiving hemodialysis in the United States. Clin J Am Soc Nephrol. 2020;15(11):1603–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther. 1999;21(3):432–41.

Article  CAS  PubMed  Google Scholar 

Bailie GR, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial. 2002;15(5):352–7.

Article  PubMed  Google Scholar 

Cozzolino M, Brancaccio D. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. Expert Opin Pharmacother. 2008;9(6):947–54.

Article  CAS  PubMed  Google Scholar 

Dennis VC, Albertson GL. Doxercalciferol treatment of secondary hyperparathyroidism. Ann Pharmacother. 2006;40(11):1955–65.

Article  CAS  PubMed  Google Scholar 

Drueke TB, McCarron DA. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med. 2003;349(5):496–9.

Article  PubMed  Google Scholar 

Kim G, Sprague SM. Use of vitamin D analogs in chronic renal failure. Adv Ren Replace Ther. 2002;9(3):175–83.

Article  PubMed  Google Scholar 

Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998;9(8):1427–32.

Article  CAS  PubMed  Google Scholar 

Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. The Cochrane database of systematic reviews. 2009;4:CD008175.

Google Scholar 

Dialysis Outcomes and Practice Patterns. DOPPS Practice Monitor-Hemodialysis; 2024. Available from: https://www.dopps.org/DPM-HD/. Accessed 16 Jan 2024.

Block GA, Martin KJ, de Francisco AL, Tur